117 related articles for article (PubMed ID: 18091378)
41. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
42. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function.
Singer C; Rasmussen A; Smith HS; Lippman ME; Lynch HT; Cullen KJ
Cancer Res; 1995 Jun; 55(11):2448-54. PubMed ID: 7757999
[TBL] [Abstract][Full Text] [Related]
43. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO
Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675
[TBL] [Abstract][Full Text] [Related]
44. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
45. Expression of parathyroidlike protein in normal, proliferative, and neoplastic human breast tissues.
Liapis H; Crouch EC; Grosso LE; Kitazawa S; Wick MR
Am J Pathol; 1993 Oct; 143(4):1169-78. PubMed ID: 8214010
[TBL] [Abstract][Full Text] [Related]
46. Relaxin-like factor (RLF) is differentially expressed in the normal and neoplastic human mammary gland.
Hombach-Klonisch S; Buchmann J; Sarun S; Fischer B; Klonisch T
Cancer; 2000 Dec; 89(11):2161-8. PubMed ID: 11147585
[TBL] [Abstract][Full Text] [Related]
47. Increased serum YKL-40 in patients with pulmonary sarcoidosis--a potential marker of disease activity?
Johansen JS; Milman N; Hansen M; Garbarsch C; Price PA; Graudal N
Respir Med; 2005 Apr; 99(4):396-402. PubMed ID: 15763444
[TBL] [Abstract][Full Text] [Related]
48. Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases.
Shabani N; Mylonas I; Kunert-Keil C; Briese V; Janni W; Gerber B; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1761-4. PubMed ID: 16033096
[TBL] [Abstract][Full Text] [Related]
49. YKL-40 protein expression in the early developing human musculoskeletal system.
Johansen JS; Høyer PE; Larsen LA; Price PA; Møllgård K
J Histochem Cytochem; 2007 Dec; 55(12):1213-28. PubMed ID: 17712177
[TBL] [Abstract][Full Text] [Related]
50. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
51. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?
Coskun U; Yamac D; Gulbahar O; Sancak B; Karaman N; Ozkan S
Neoplasma; 2007; 54(4):348-52. PubMed ID: 17845129
[TBL] [Abstract][Full Text] [Related]
52. Serum YKL-40 and colorectal cancer.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Br J Cancer; 1999 Mar; 79(9-10):1494-9. PubMed ID: 10188896
[TBL] [Abstract][Full Text] [Related]
53. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
Høgdall EV; Johansen JS; Kjaer SK; Price PA; Christensen L; Blaakaer J; Bock JE; Glud E; Høgdall CK
Oncol Rep; 2003; 10(5):1535-8. PubMed ID: 12883737
[TBL] [Abstract][Full Text] [Related]
54. Serum YKL-40, a new prognostic biomarker in cancer patients?
Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
[TBL] [Abstract][Full Text] [Related]
55. Surfactant protein A expression in human normal and neoplastic breast epithelium.
Braidotti P; Cigala C; Graziani D; Del Curto B; Dessy E; Coggi G; Bosari S; Pietra GG
Am J Clin Pathol; 2001 Nov; 116(5):721-8. PubMed ID: 11710690
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
57. [YKL 40: marker of disease activity in rheumatoid arthritis?].
Morgante M; Di Munno O; Morgante D
Minerva Med; 1999; 90(11-12):437-41. PubMed ID: 10829806
[TBL] [Abstract][Full Text] [Related]
58. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
59. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
60. Concentration and localization of YKL-40 in hip joint diseases.
Kawasaki M; Hasegawa Y; Kondo S; Iwata H
J Rheumatol; 2001 Feb; 28(2):341-5. PubMed ID: 11246673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
